Letters Data Sharing Statement: See Supplement 4. This finding is consistent with randomized trials of prophy- 2,3 lactic hydrocortisone treatment. The effect size of the 1. Onland W, Cools F, Kroon A, et al; STOP-BPD Study Group. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or reduction in mortality in favor of hydrocortisone at 2-year bronchopulmonary dysplasia among very preterm infants receiving mechanical follow-up was similar to the previous report at 36 weeks’ ventilation: a randomized clinical trial. JAMA. 2019;321(4):354-363. doi:10.1001/ postmenstrual age (OR, 0.59) but no longer reached statisti- jama.2018.21443 cal significance. 2. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C; PREMILOC Trial Group. Association between early low-dose hydrocortisone therapy in The high proportion of open-label hydrocortisone treat- extremely preterm neonates and neurodevelopmental outcomes at 2 years of ment in the placebo group may have diluted a possible effect age. JAMA. 2017;317(13):1329-1337. doi:10.1001/jama.2017.2692 of hydrocortisone, although the modulating effect of open- 3. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for label steroids on long-term outcome is probably limited. The preventing or treating bronchopulmonary dysplasia in preterm infants: possible beneficial hydrocortisone effect on survival needs fur- a systematic review.
JAMA – American Medical Association
Published: Jul 27, 2021